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Eisease Management
or Nondepressed Heart
ailure Patients Only
act or Artifact?
aarsma et al. (1) present a post hoc subgroup analysis from the
OACH (Coordinating study evaluating Outcomes of Advising
nd Counseling in Heart failure) trial that poses the hypothesis
hat disease management is beneficial in nondepressed heart failure
atients but increases mortality in patients with comorbid depres-
ion. Significant test results for interaction of treatment allocation
nd baseline depression support this concept.
The data indicate that 32% of 201 nondepressed and 21% of
16 depressed control subjects died (hazard ratio [HR]: 0.61, 95%
onfidence interval [CI]: 0.38 to 0.97, p  0.036). In the
ntervention arm, 22% of 380 nondepressed and 32% of 261
epressed patients died (HR: 1.56, 95% CI: 1.15 to 2.11, p 
.004). Thus, whereas for the intervention arm, mortality risk
oncurred with numerous publications unanimously reporting
ugmented mortality in depressed cardiovascular patients (e.g.,
iang et al. [2]; HR: 1.36, 95% CI: 1.09 to 1.70), the reverse was
bserved in the control subjects.
Actually, a mortality risk comparable to that reported in observa-
ional studies would also have been expected in the control subjects.
s no intervention was applied, superior survival of depressed control
atients is not attributable to specific care. Conversely, had disease
anagement exerted a beneficial effect in the nondepressed patients
hile worsening survival in the depressed patients, as the investigators
ropose, a larger mortality difference with a distinctly higher than
eported mortality risk in the depressed patients would have been
nticipated with the intervention. We, therefore, propose to interpret
he reported interaction as a false positive finding, probably caused by
data artifact in the control group.
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eply
e appreciate the interest expressed by Dr. Gelbrich and col-
eagues in our work (1). We examined the effect of a disease
anagement program (DMP) in 958 heart failure (HF) patients,
nd we found an interaction between depressive symptoms at
aseline and the effect of such a program. In the overall sample,
here was no significant effect of DMP on the composite primary
nd point. The effect of the DMP was significantly different in
ondepressed than in depressed HF patients (1).
As mentioned by Dr. Gelbrich and colleagues, an expected
ugmented mortality in depressed patients was seen in the de-
ressed intervention patients but not in the control subjects. Dr.
elbrich and colleagues argue that the mortality risk of the control
ubjects was low and should have been comparable to that reported
n observational studies.
We feel it is important to point out that we found that depressed
atients had a higher mortality (29%) when compared with the
ondepressed patients (26%). We also recently published a report (2)
hat in patients with HF, depression is independently associated with
oor outcomes. We reported a lower mortality risk in the depressed
atients in the control group; however, this mortality risk (21% died
ithin 18 months) is not extremely low (3) and does not dismiss the
ata from this large multicenter trial as invalid.
Dr. Gelbrich and colleagues also argue that—as we hypothesize in
he discussion—if disease management has a beneficial effect in the
ondepressed and not in the depressed patients, the mortality differ-
nce would have been expected to be larger. We are not aware of any
tudies that confirm this argument of the size of the effect. It is not at
ll clear how large an effect of an intervention in depressed patients
ould be. At this moment, there are no trials that specifically tailor
nterventions and treatment to HF patients, so effect sizes are not
nown.
We do believe that the data from this large-scale study are
aluable to consider in further developing DMP for patients with
F and that the findings should not be qualified as an artifact.
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